Merus N.V v. Assistant Controller of Patents and Designs, Government of India

When a patent application hits a wall at the examiner's desk, the instinct is often to abandon ship. But what if the rejection itself reveals a path forward — one that requires sharpening your claims rather than scrapping them? The dispute between Merus N.V. and the Assistant Controller of Patents is a masterclass in how the right kind of amendment can turn a refused application into a granted patent. For founders navigating the choppy waters of IP prosecution, this case offers a critical lesson: the line between permissible refinement and impermissible expansion is thinner than you think, and knowing where it lies can make or break your invention.

Merus N.V., a biotech innovator, found itself at an impasse with the Indian Patent Office over its Patent Application No. 467/CHENP/2011. The Assistant Controller of Patents had rejected the application on the grounds of non-patentability under Section 3(i) and Section 3(j) of the Indian Patents Act — provisions that exclude certain categories of inventions from protection. Rather than accept the rejection, Merus N.V. chose to fight, escalating the matter to the High Court. At the heart of the dispute was a pivotal question: had Merus overstepped by amending its claims during prosecution, or had it simply refined the scope to address the Controller's objections while preserving the essence of its invention?

Merus N.V. argued that the amendments it introduced during prosecution were not a wholesale rewrite of the application but a careful narrowing of the claims — specifically, a refinement directed toward nucleic acid molecules. According to the appellant, this refinement retained the core invention intact while addressing the substantive objections raised by the Controller. The implication was clear: Merus was not trying to sneak in new matter; it was trying to meet the patentability requirements head-on. The respondent, the Assistant Controller, stood by the rejection, presumably contending that the amendments either broadened the scope beyond what was originally disclosed or failed to overcome the fundamental non-patentability objections under Sections 3(i) and 3(j). The legal friction centered on a classic prosecution dilemma: where is the boundary between legitimate claim refinement and impermissible alteration?

The High Court sided with Merus N.V., finding merit in the appellant's argument that the amendments fell within the permissible scope of prosecution refinements. The court accepted that narrowing claims to nucleic acid molecules was a legitimate response to the Controller's objections and did not constitute an impermissible departure from the original disclosure. By recognizing that the amendments preserved the core invention while addressing the patentability concerns, the court effectively reversed the rejection. The outcome was a clear win for the patent applicant — a reminder that the judiciary will look beyond the surface of a rejection to assess whether amendments genuinely serve the prosecution process or overreach it.

For founders and IP professionals, this case delivers a sharp, practical lesson: amendments during patent prosecution are not inherently suspect. If you face a rejection, the right move may be to refine your claims — narrowing scope, clarifying language, or focusing on specific embodiments — rather than abandoning the application. The key is ensuring that every amendment stays within the boundaries of your original disclosure and retains the core inventive concept. Before amending, ask yourself: does this change address the examiner's objection, or does it introduce new matter? If the former, you are on solid ground. Document your reasoning, tie each amendment to the original specification, and you may turn a rejection into a granted patent — just as Merus N.V. did.